Electrosprayable Levan-Coated Nanoclusters and Ultrasound-Responsive Drug Delivery for Cancer Therapy
Source abstract
Abstract
In this study, we synthesized levan shell hydrophobic silica nanoclusters encapsulating doxorubicin (L-HSi-Dox) and evaluated their potential as ultrasound-responsive drug delivery systems for cancer treatment. L-HSi-Dox nanoclusters were successfully fabricated by integrating a hydrophobic silica nanoparticle-doxorubicin complex as the core and an amphiphilic levan carbohydrate polymer as the shell by using an electrospray technique. Characterization analyses confirmed the stability, size, and composition of the nanoclusters. In particular, the nanoclusters exhibited a controlled release of Dox under aqueous conditions, demonstrating their potential as efficient drug carriers. The levanic groups of the nanoclusters enhanced the targeted delivery of Dox to specific cancer cells. Furthermore, the synergism between the nanoclusters and ultrasound effectively reduced cell viability and induced cell death, particularly in the GLUT5-overexpressing MDA-MB-231 cells. In a tumor xenograft mouse model, treatment with the nanoclusters and ultrasound significantly reduced the tumor volume and weight without affecting the body weight. Collectively, these results highlight the potential of the L-HSi-Dox nanoclusters and ultrasound as promising drug delivery systems with an enhanced therapeutic efficacy for biomedical applications.
Source: openalex_inverted_index · Quality: baseline
Research context
OpenAlex topics: Nanoparticle-Based Drug Delivery · Microbial Metabolites in Food Biotechnology · Electrohydrodynamics and Fluid Dynamics
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
Affiliations
School of Chemical Engineering, Yeungnam University, Gyeongsan 38541, South Korea
Department of Bioengineering and Nano-bioengineering, Incheon National University, Incheon 22012, South Korea
Division of Bioengineering, Incheon National University, Incheon 22012, South Korea
Funding
National Research Foundation of Korea
References (57)
Show source-provided references
1. 10.1080/10717544.2018.142577810.1080/10717544.2018.1425778 ↗
2. 10.1126/science.109550510.1126/science.1095505 ↗
3. 10.1166/jbn.2017.235610.1166/jbn.2017.2356 ↗
4. 10.1016/j.pcad.2006.10.00210.1016/j.pcad.2006.10.002 ↗
5. 10.1111/j.2042-7158.2012.01567.x10.1111/j.2042-7158.2012.01567.x ↗
6. 10.1016/j.yjmcc.2012.03.00610.1016/j.yjmcc.2012.03.006 ↗
7. 10.1038/srep2385910.1038/srep23859 ↗
8. 10.1021/ja207150n10.1021/ja207150n ↗
9. 10.1016/j.ijpharm.2020.12011710.1016/j.ijpharm.2020.120117 ↗
10. 10.2147/IJN.S1949110.2147/IJN.S19491 ↗
11. 10.2147/IJN.S19317010.2147/IJN.S193170 ↗
12. 10.1016/j.apsb.2015.07.00310.1016/j.apsb.2015.07.003 ↗
13. 10.1021/acs.molpharmaceut.0c0038910.1021/acs.molpharmaceut.0c00389 ↗
14. 10.1038/s41565-018-0342-510.1038/s41565-018-0342-5 ↗
15. 10.1039/c3sc22205e10.1039/c3sc22205e ↗
16. 10.1039/C4CC07679F10.1039/C4CC07679F ↗
17. 10.1073/pnas.93.5.184710.1073/pnas.93.5.1847 ↗
18. 10.3390/pharmaceutics1404082810.3390/pharmaceutics14040828 ↗
19. 10.1016/j.biotechadv.2016.05.00210.1016/j.biotechadv.2016.05.002 ↗
20. 10.1016/j.bej.2014.06.02010.1016/j.bej.2014.06.020 ↗
21. 10.1016/j.tibs.2015.12.00110.1016/j.tibs.2015.12.001 ↗
22. 10.1016/j.carbpol.2010.11.04610.1016/j.carbpol.2010.11.046 ↗
23. 10.1016/j.carbpol.2016.12.02510.1016/j.carbpol.2016.12.025 ↗
24. 10.1016/j.carbpol.2016.05.02110.1016/j.carbpol.2016.05.021 ↗
25. 10.1016/j.carbpol.2015.09.09310.1016/j.carbpol.2015.09.093 ↗
26. 10.3390/ijms2006150210.3390/ijms20061502 ↗
27. 10.1016/j.jconrel.2010.07.11710.1016/j.jconrel.2010.07.117 ↗
28. 10.1063/1.475736510.1063/1.4757365 ↗
29. 10.1016/j.nantod.2014.04.00810.1016/j.nantod.2014.04.008 ↗
30. 10.1002/anie.20150174810.1002/anie.201501748 ↗
31. 10.1016/S0005-2736(00)00363-110.1016/S0005-2736(00)00363-1 ↗
32. 10.1021/acsami.0c0747310.1021/acsami.0c07473 ↗
33. 10.1016/S0927-7757(03)00138-910.1016/S0927-7757(03)00138-9 ↗
34. 10.1177/014459871771628110.1177/0144598717716281 ↗
35. 10.1691/ph.2011.037910.1691/ph.2011.0379 ↗
36. 10.1021/acs.molpharmaceut.7b0109110.1021/acs.molpharmaceut.7b01091 ↗
37. 10.1038/nbt.333010.1038/nbt.3330 ↗
38. 10.3390/nano1005084710.3390/nano10050847 ↗
39. 10.1016/j.jconrel.2015.11.00910.1016/j.jconrel.2015.11.009 ↗
40. 10.1186/s40824-019-0166-x10.1186/s40824-019-0166-x ↗
41. 10.1038/srep0216210.1038/srep02162 ↗
42. 10.1016/S0009-2509(03)00234-310.1016/S0009-2509(03)00234-3 ↗
43. 10.1155/2010/78017110.1155/2010/780171 ↗
44. 10.1039/C8RA05929B10.1039/C8RA05929B ↗
45. 10.1002/anie.20130115510.1002/anie.201301155 ↗
46. 10.1021/ac801435610.1021/ac8014356 ↗
47. 10.1039/C8CC09389J10.1039/C8CC09389J ↗
48. 10.3390/pharmaceutics1309139610.3390/pharmaceutics13091396 ↗
49. 10.1016/j.jconrel.2015.03.00410.1016/j.jconrel.2015.03.004 ↗
50. 10.1007/s12257-018-0070-610.1007/s12257-018-0070-6 ↗
51. 10.2307/404105810.2307/4041058 ↗
52. 10.1186/s13046-018-1018-610.1186/s13046-018-1018-6 ↗
53. 10.1016/S0006-3495(03)70034-410.1016/S0006-3495(03)70034-4 ↗
54. 10.3389/fbioe.2019.0032410.3389/fbioe.2019.00324 ↗
55. 10.1016/j.bbcan.2013.12.00210.1016/j.bbcan.2013.12.002 ↗
56. 10.1016/j.cell.2020.02.00110.1016/j.cell.2020.02.001 ↗
57. 10.1186/s12951-022-01243-w10.1186/s12951-022-01243-w ↗